Loading...
•
Dec 31, 2023
LivaNova Q4 2023 Earnings Report
Reported strong revenue growth and EPS, driven by solid performance in Cardiopulmonary and Neuromodulation segments.
Key Takeaways
LivaNova reported a strong Q4 2023, with revenue increasing by 12.8% to $310.1 million and U.S. GAAP diluted earnings per share of $0.30. Adjusted diluted earnings per share was $0.87. The company provided full-year 2024 guidance, expecting revenue growth between 4% and 5% on a constant-currency basis and adjusted diluted earnings per share in the range of $2.95 to $3.05.
Fourth-quarter revenue increased 12.8 percent on a reported basis and 11.9 percent on a constant-currency basis.
U.S. GAAP diluted earnings per share was $0.30 and adjusted diluted earnings per share was $0.87.
The company initiated a wind down of the Advanced Circulatory Support segment in January 2024.
Vladimir A. Makatsaria was named the Company's Chief Executive Officer (CEO) and member of the Board of Directors, effective March 1, 2024.
LivaNova
LivaNova
LivaNova Revenue by Segment
LivaNova Revenue by Geographic Location
Revenue by Segment
Cardiopulmonary Revenue
CapyFin.comNeuromodulation Revenue
CapyFin.comOther Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comEurope Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
LivaNova expects revenue for full-year 2024 to grow between 4 and 5 percent on a constant-currency basis. When excluding the impact of the ACS segment wind down, the Company expects revenue for full-year 2024 to grow between 6 and 7 percent on a constant-currency basis. Adjusted diluted earnings per share for 2024 are expected to be in the range of $2.95 to $3.05.
Positive Outlook
- Revenue for full-year 2024 to grow between 4 and 5 percent on a constant-currency basis.
- Revenue for full-year 2024 to grow between 6 and 7 percent on a constant-currency basis, excluding the impact of the ACS segment wind down.
- Foreign currency is expected to be negligible based on current exchange rates.
- Adjusted diluted earnings per share for 2024 are expected to be in the range of $2.95 to $3.05.
- Adjusted free cash flow will be in the range of $95 to $115 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income